The present invention relates to novel compounds of formula (I) or apharmaceutically acceptable salt thereof, wherein G is selected from a groupconsisting of: phenyl, pyridyl, benzothiazolyl, indazolyl； p is an integerranging from 0 to 5； R1 is independently selected from a group consisting of:halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy,C1-4alkanoyl； or corresponds to a group R5； R2 is hydrogen or C1-4alkyl； R3 isC1-4alkyl； R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any ofwhich groups is optionally substituted by 1, 2, 3 or 4 substituents selectedfrom the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl； R5 is a moiety selected from the group consisting of:isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl,thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionallysubstituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl； and when R1 is chlorine and pis 1, such R1 is not present in the ortho position with respect to the linkingbond to the rest of the molecule； and when R1 corresponds to R5, p is 1；processes for their preparation, intermediates used in these processes,pharmaceutical compositions containing them and their use in therapy, asmodulators of dopamine D3 receptors, e.g. to treat drug dependency or asantipsychotic agents.
